Evidence map›Paper›PMID 30557391›Full record

ArticlePloS one2018

Small-molecule induction of Aβ-42 peptide production in human cerebral organoids to model Alzheimer's disease associated phenotypes.

Serena Pavoni, Rafika Jarray, Ferid Nassor, Anne-Cécile Guyot, Steve Cottin, Jessica Rontard, Jacqueline Mikol, Aloïse Mabondzo, Jean-Philippe Deslys, Frank Yates

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Current Development of iPSC-Based Modeling in Neurodegenerative Diseases.International journal of molecular sciences · 2025
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Serena PavoniService d'Etude des Prions et Infections Atypiques (SEPIA), Institut François Jacob, CEA, Université Paris-Saclay, Fontenay-aux-Roses, France.ORCID 0000-0001-8722-088X
Rafika JarrayService d'Etude des Prions et Infections Atypiques (SEPIA), Institut François Jacob, CEA, Université Paris-Saclay, Fontenay-aux-Roses, France.
Ferid NassorService d'Etude des Prions et Infections Atypiques (SEPIA), Institut François Jacob, CEA, Université Paris-Saclay, Fontenay-aux-Roses, France.
Anne-Cécile GuyotLaboratory of Drug Metabolism Research (LEMM), Institute of Biology and Technology Saclay (IBITECS), CEA, Université Paris-Saclay, Gif-sur-Yvette, France.
Steve CottinService d'Etude des Prions et Infections Atypiques (SEPIA), Institut François Jacob, CEA, Université Paris-Saclay, Fontenay-aux-Roses, France.ORCID 0000-0002-5339-0677
Jessica RontardService d'Etude des Prions et Infections Atypiques (SEPIA), Institut François Jacob, CEA, Université Paris-Saclay, Fontenay-aux-Roses, France.
Jacqueline MikolService d'Etude des Prions et Infections Atypiques (SEPIA), Institut François Jacob, CEA, Université Paris-Saclay, Fontenay-aux-Roses, France.
Aloïse MabondzoLaboratory of Drug Metabolism Research (LEMM), Institute of Biology and Technology Saclay (IBITECS), CEA, Université Paris-Saclay, Gif-sur-Yvette, France.
Jean-Philippe DeslysService d'Etude des Prions et Infections Atypiques (SEPIA), Institut François Jacob, CEA, Université Paris-Saclay, Fontenay-aux-Roses, France.
Frank YatesService d'Etude des Prions et Infections Atypiques (SEPIA), Institut François Jacob, CEA, Université Paris-Saclay, Fontenay-aux-Roses, France.ORCID 0000-0002-3590-5745
Commissariat à l'Énergie Atomique et aux Énergies Alternatives · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human mini-brains (MB) are cerebral organoids that recapitulate in part the complexity of the human brain in a unique three-dimensional in vitro model, yielding discrete brain regions reminiscent of the cerebral cortex. Specific proteins linked to neurodegenerative disorders are physiologically expressed in MBs, such as APP-derived amyloids (Aβ), whose physiological and pathological roles and interactions with other proteins are not well established in humans. Here, we demonstrate that neuroectodermal organoids can be used to study the Aβ accumulation implicated in Alzheimer's disease (AD). To enhance the process of protein secretion and accumulation, we adopted a chemical strategy of induction to modulate post-translational pathways of APP using an Amyloid-β Forty-Two Inducer named Aftin-5. Secreted, soluble Aβ fragment concentrations were analyzed in MB-conditioned media. An increase in the Aβ42 fragment secretion was observed as was an increased Aβ42/Aβ40 ratio after drug treatment, which is consistent with the pathological-like phenotypes described in vivo in transgenic animal models and in vitro in induced pluripotent stem cell-derived neural cultures obtained from AD patients. Notably in this context we observe time-dependent Aβ accumulation, which differs from protein accumulation occurring after treatment. We show that mini-brains obtained from a non-AD control cell line are responsive to chemical compound induction, producing a shift of physiological Aβ concentrations, suggesting that this model can be used to identify environmental agents that may initiate the cascade of events ultimately leading to sporadic AD. Increases in both Aβ oligomers and their target, the cellular prion protein (PrPC), support the possibility of using MBs to further understand the pathophysiological role that underlies their interaction in a human model. Finally, the potential application of MBs for modeling age-associated phenotypes and the study of neurological disorders is confirmed.

Indexed as

PhenotypeAlzheimer DiseaseAmyloid beta-PeptidesBrainGene Expression RegulationHumansOrganoidsPeptide FragmentsProtein MultimerizationProtein Structure, QuaternaryPrPC ProteinsSmall Molecule LibrariesAmyloid beta-Peptidesamyloid beta-protein (1-42)amyloid beta-protein (40-42)Peptide FragmentsPrPC ProteinsSmall Molecule Libraries

Identifiers

PMID30557391
PMCPMC6296660
OpenAlexW2903572769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.